Briacell presents phase 3 biomarker data at ESMO 2025

Dr. William Williams reports BRIACELL PRESENTS PHASE 3 CLINICAL BIOMARKER DATA AT ESMO 2025 Briacell Therapeutics Corp. has released encouraging clinical biomarker data in its continuing pivotal phase 3 study of Bria-IMT plus an immune check point inhibitor (CPI) in metastatic breast cancer. The findings are being presented in Briacell's poster presentation at the European Society for Medical Oncology (ESMO) Congress 2025 Annual Meeting taking place Oct. 17 to Oct. 21, 2025, in Berlin, Germany. The phase 3 data shown are for all patients evaluated regardless of treatment assignment (that is, is blinded). Biomarkers identified in Briacell's phase 2 study are showing similar and encouraging trends in the continuing pivotal phase 3 study of Bria-IMT in metastatic breast cancer (MBC). No new safety or tolerability issues identified in pooled analysis of continuing pivotal phase 3 study. "We are encouraged by the early constructive clinical biomarker data which could allow us to predict clinical and survival outcomes in our patients and would help guide treatment decisions for metastatic breast cancer patients with limited options," stated Dr. William V. Williams, Briacell's president and chief executive officer. Poster No. 3928: Feasibility and Biomarker Validation of an International Randomized Phase 3 Trial of Bria-IMT Cell Therapy in Late Stage MBC (BRIA-ABC) In Briacell's pivotal phase 3 study of Bria-IMT plus an immune check point inhibitor (CPI) in metastatic breast cancer, patients are randomized 1:1:1 to Bria-IMT + CPI, Treatment of Physician's Choice, or Bria-IMT monotherapy. As of the time of the poster submission, pooled data was available in 113 patients, with a median of six prior lines of treatment (two to 13). Evaluable only pertains to imaging. All 113 are evaluated for safety, PFS (preliminary feasibility study), et cetera. As reported in the phase 2 study, neutrophil to lymphocyte ratio (NLR) continues to be a potential biomarker of clinical benefit as progression free survival (PFS) was significantly higher in patients with NLR of 0.7 to 2.3 (4.5 months) versus those with NLR less than 0.7 or greater than 2.3 (2.5 months) (HR) of 0.5 (95-per-cent CI 0.3 to 0.8, p equals 0.005). In the phase 3 study, PFS data comparing Briacell's Bria-IMT combination regimen versus those treated with physician's choice remains blinded at this time. Bria-IMT has been well tolerated in the phase 3 study with no treatment-related discontinuations due to adverse events (AEs). The most common AEs are minor, including fatigue, anemia and nausea. About Briacell's pivotal phase 3 clinical study of Bria-IMT combination regimen in MBC patients Briacell's pivotal phase 3 study of Bria-IMT plus an immune check point inhibitor (CPI) in metastatic breast cancer is continuing. Interim data will be analyzed once 144 patient events (deaths) occur, comparing the overall survival (OS) in patients treated with the Bria-IMT combination regimen versus those treated with physician's choice as the primary endpoint. Positive results of the pivotal phase 3 study could result in full approval and marketing authorization for Bria-IMT in MBC patients. Briacell reported positive phase 2 survival data in a similar MBC patient population treated with the same Bria-IMT combination regimen. The Bria-IMT combination regimen has received FDA (Food and Drug Administration) fast-track designation. About Briacell Therapeutics Corp. Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. We seek Safe Harbor.